This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone revenue jumps but profit falls and operating cash flow is negative
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone results for the quarter ended 30 September 2026 showed revenue from operations of Rs 562.45 lakh, up from Rs 189.10 lakh a year earlier. Profit after tax fell to Rs 3.03 lakh from Rs 7.14 lakh. The calculated EBITDA margin improved from negative 21.42% to negative 1.42%. The half-year cash flow shows negative operating cash flow. The board approved the unaudited results after the statutory auditor's limited review.
Revenue growth and a much less negative operating margin help, but lower profit and negative operating cash flow could keep sentiment cautious.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹5.62 Cr | ₹4.89 Cr | +15.0% |
| Operating profit | −₹0.11 Cr | −₹0.02 Cr | loss widened |
| Profit after tax | ₹0.03 Cr | ₹0.07 Cr | −57.6% |
| EBITDA margin | -1.4% | 0.3% | −1.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.